Pfizer Vaccine Report

FDA approves First RSV vaccine for adults under 60

FDA expands Pfizer’s RSV vaccine label to include all high-risk adults

Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults over 18 years of age.

McKnight's Long-Term Care News · 1d

FDA OKs Pfizer’s RSV vaccine for some adults under 60

On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for people 18 to 59 who are more vulnerable to the virus.

Wall Street Journal · 2d

Pfizer Receives Expanded FDA Approval for RSV Vaccine

Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker said.

The American Journal of Manage… · 1d

FDA Approves Abrysvo RSV Vaccine for Adults at Increased Risk

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

Reuters on MSN · 2d

US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.

Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

Pfizer (PFE) Receives a Hold from J.P. Morgan

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00. The ...

11h

Merck, Pfizer lifted as CDC backs broader use of pneumococcal vaccines

An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple ...

2don MSN

Q&A on the 2024-2025 COVID-19 Vaccines

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

FiercePharma1d

In boon for Pfizer and Merck, CDC panel backs expanded use of pneumococcal vaccines

With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...

The Citizen3d

After investigation, Covid vaccine mandates just look bad, even corrupt

In last week’s column, I told you how the 2024 General Election (early voting has started) could lead to healthier, smarter, and longer lives for all of us (see: ...

Mixed Prospects and Uncertainty Lead to Hold Rating for Pfizer Amid COVID-19 Revenue Fluctuations

Analyst Mohit Bansal from Wells Fargo maintained a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at $30.00.

Starboard Value CEO says Pfizer's board should hold management accountable

Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold ...

Zacks.com on MSN1d

Should You Buy, Sell or Hold Pfizer Stock Before Q3 Earnings?

Pfizer PFE will report its third-quarter 2024 earnings on Oct. 29, before market open. The Zacks Consensus Estimate for sales ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results